{"id":78773,"date":"2026-09-04T16:20:19","date_gmt":"2026-09-04T08:20:19","guid":{"rendered":"https:\/\/flcube.com\/?p=78773"},"modified":"2026-09-04T16:20:20","modified_gmt":"2026-09-04T08:20:20","slug":"stoke-and-biogen-to-present-5-year-zorevunersen-data-in-dravet-syndrome-at-european-epilepsy-congress","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78773","title":{"rendered":"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Stoke Therapeutics (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/STOK:NASDAQ\">NASDAQ: STOK<\/a>)<\/strong> and <strong>Biogen Inc. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>)<\/strong> announced that they will present clinical data on <strong>zorevunersen<\/strong> for the treatment of <strong>Dravet syndrome<\/strong> at the <strong>16th European Epilepsy Congress (EEC)<\/strong>, taking place <strong>September 5\u20139 in Athens, Greece<\/strong>. The presentation will showcase more than <strong>5 years of clinical experience<\/strong> with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.<\/p>\n\n\n\n<h2 id=\"h-presentation-overview\" class=\"wp-block-heading\">Presentation Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Companies<\/td><td><strong>Stoke Therapeutics (NASDAQ: STOK)<\/strong> and <strong>Biogen Inc. (NASDAQ: BIIB)<\/strong><\/td><\/tr><tr><td>Product<\/td><td><strong>zorevunersen<\/strong><\/td><\/tr><tr><td>Indication<\/td><td><strong>Dravet syndrome<\/strong><\/td><\/tr><tr><td>Venue<\/td><td><strong>16th European Epilepsy Congress (EEC)<\/strong>, Athens, Greece<\/td><\/tr><tr><td>Congress Dates<\/td><td>05\u201309 Sept 2026<\/td><\/tr><tr><td>Announcement Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Data Scope<\/td><td>More than 5 years of clinical experience, including two Phase I\/IIa studies and ongoing open-label extension studies (OLEs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>zorevunersen<\/strong>, an investigational antisense oligonucleotide being developed for <strong>Dravet syndrome<\/strong>, a severe and treatment-resistant developmental and epileptic encephalopathy<\/li>\n\n\n\n<li><strong>Development Partners:<\/strong> Jointly advanced by <strong>Stoke Therapeutics<\/strong> and <strong>Biogen<\/strong>, combining Stoke\u2019s RNA-targeting platform with Biogen\u2019s neurology development and commercial scale<\/li>\n\n\n\n<li><strong>Evidence Base:<\/strong> Clinical data span two <strong>Phase I\/IIa studies<\/strong> and ongoing <strong>open-label extension studies (OLEs)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-long-term-ole-results\" class=\"wp-block-heading\">Clinical Evidence \u2013 Long-Term OLE Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Outcome<\/th><th>4-Year OLE Finding<\/th><\/tr><\/thead><tbody><tr><td>Seizure burden<\/td><td>Substantial and durable reductions<\/td><\/tr><tr><td>Cognition<\/td><td>Continuing improvements<\/td><\/tr><tr><td>Behavior<\/td><td>Continuing improvements<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The four-year OLE data represent the longest available follow-up on <strong>zorevunersen<\/strong> in <strong>Dravet syndrome<\/strong> patients. Beyond seizure control \u2014 the conventional primary metric in epilepsy trials \u2014 the sustained improvements in <strong>cognition and behavior<\/strong> address the broader developmental burden of the disease, a dimension where most existing therapies offer little meaningful benefit.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Durability as differentiator:<\/strong> Five-plus years of accumulating data strengthen the long-term efficacy and safety narrative for <strong>zorevunersen<\/strong> ahead of potential regulatory submissions<\/li>\n\n\n\n<li><strong>Beyond seizures:<\/strong> Cognitive and behavioral gains could position the therapy as disease-modifying rather than purely symptomatic \u2014 a critical distinction for pricing, reimbursement and clinical adoption in rare epileptic encephalopathies<\/li>\n\n\n\n<li><strong>Scientific visibility:<\/strong> Presentation at the <strong>European Epilepsy Congress<\/strong> puts the data directly in front of the treating neurologist community that drives prescribing decisions in Dravet syndrome<\/li>\n\n\n\n<li><strong>Partnership momentum:<\/strong> The joint presentation reinforces the <strong>Stoke\u2013Biogen<\/strong> alliance and Biogen\u2019s continued investment in rare neurological disease franchises<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding clinical data interpretation, regulatory pathways and commercial potential are forward-looking and subject to risks and uncertainties, including trial outcomes, regulatory decisions and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[351,17,993,4927,3714],"class_list":["post-78773","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biogen","tag-clinical-trial-results","tag-nasdaq-biib","tag-nasdaq-stok","tag-stoke-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5\u20139 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78773\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress\" \/>\n<meta property=\"og:description\" content=\"Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5\u20139 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78773\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:20:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T08:20:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78773#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78773\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress\",\"datePublished\":\"2026-09-04T08:20:19+00:00\",\"dateModified\":\"2026-09-04T08:20:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78773\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biogen\",\"Clinical trial results\",\"NASDAQ: BIIB\",\"NASDAQ: STOK\",\"Stoke Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78773#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78773\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78773\",\"name\":\"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T08:20:19+00:00\",\"dateModified\":\"2026-09-04T08:20:20+00:00\",\"description\":\"Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5\u20139 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78773#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78773\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78773#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress - Insight, China&#039;s Pharmaceutical Industry","description":"Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5\u20139 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78773","og_locale":"en_US","og_type":"article","og_title":"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress","og_description":"Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5\u20139 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.","og_url":"https:\/\/flcube.com\/?p=78773","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:20:19+00:00","article_modified_time":"2026-09-04T08:20:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78773#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78773"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress","datePublished":"2026-09-04T08:20:19+00:00","dateModified":"2026-09-04T08:20:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78773"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biogen","Clinical trial results","NASDAQ: BIIB","NASDAQ: STOK","Stoke Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78773#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78773","url":"https:\/\/flcube.com\/?p=78773","name":"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T08:20:19+00:00","dateModified":"2026-09-04T08:20:20+00:00","description":"Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical data on zorevunersen for the treatment of Dravet syndrome at the 16th European Epilepsy Congress (EEC), taking place September 5\u20139 in Athens, Greece. The presentation will showcase more than 5 years of clinical experience with the antisense oligonucleotide candidate, including four-year open-label extension results demonstrating substantial and durable seizure reductions alongside continuing cognitive and behavioral improvements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78773#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78773"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78773#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78773"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78773\/revisions"}],"predecessor-version":[{"id":78774,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78773\/revisions\/78774"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}